Clinical Trial Update: Effect of ARC1779 on Cerebral Microembolism in Patients Undergoing Carotid Endarterectomy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ARC1779 to reduce cerebral microembolism during carotid endarterectomy was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carotid Stenosis
• Cerebral Thromboembolism
• Intracranial Embolism

Drugs mentioned

• ARC1779

Snippet

Sponsor: Archemix Corp. | Conditions: Intracranial Embolism, Cerebral Thromboembolism | Phase 2 | Status: TERMINATED